APO Research
Talk to an analyst

APO RESEARCH · REPORT

Rheumatic Disease Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Rheumatic Disease Drugs Market Outlook and Growth Opportunities 2026

23 December 2025205 pages

Choose your research edition.

Industry ResearchRheumatic Disease Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Rheumatic Disease Drugs Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Rheumatic Disease Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Rheumatic Disease Drugs Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal Rheumatic Disease Drugs Market Analysis and Forecast 2026-2032207 pages · $4,950 USD

Market perspective

The global Rheumatic Disease Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Rheumatic Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Rheumatic Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Rheumatic Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Rheumatic Disease Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Rheumatic Disease Drugs market include Simcere, WuXi AppTec, Sanofi, Johnson & Johnson, Roche, Eli Lilly and Company, ALPHAMAB ONCOLOGY, Hengrui and Pfizer, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Rheumatic Disease Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Rheumatic Disease Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Rheumatic Disease Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Rheumatic Disease Drugs market.

Rheumatic Disease Drugs Segment by Company

Simcere

WuXi AppTec

Sanofi

Johnson & Johnson

Roche

Eli Lilly and Company

ALPHAMAB ONCOLOGY

Hengrui

Pfizer

Henlius

Bristol-Myers Squibb

Amgen

AbbVie

UCB

Mitsubishi Tanabe Pharma Corporation

IQVIA

Boehringer-Ingelheim

Aprazer

Rheumatic Disease Drugs Segment by Type

DMARDs

JAK Inhibitors

Biologics

Others

Rheumatic Disease Drugs Segment by Application

Hospital

Clinic

Others

Rheumatic Disease Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Rheumatic Disease Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Rheumatic Disease Drugs key companies, revenue, market share, and recent developments.

3. To split the Rheumatic Disease Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Rheumatic Disease Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Rheumatic Disease Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Rheumatic Disease Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rheumatic Disease Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Rheumatic Disease Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rheumatic Disease Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Rheumatic Disease Drugs industry.

Chapter 3: Detailed analysis of Rheumatic Disease Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Rheumatic Disease Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Rheumatic Disease Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Rheumatic Disease Drugs Industry Trends Table 2. Rheumatic Disease Drugs Industry Drivers Table 3. Rheumatic Disease Drugs Industry Opportunities and Challenges Table 4. Rheumatic Disease Drugs Industry Restraints Table 5. Global Rheumatic Disease Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Rheumatic Disease Drugs Revenue Share by Company (2021-2026) Table 7. Global Rheumatic Disease Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Rheumatic Disease Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Rheumatic Disease Drugs Company, Product Type & Application Table 10. Global Rheumatic Disease Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Rheumatic Disease Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of DMARDs Table 15. Significant Companies of JAK Inhibitors Table 16. Significant Companies of Biologics Table 17. Significant Companies of Others Table 18. Global Rheumatic Disease Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Rheumatic Disease Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Rheumatic Disease Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Rheumatic Disease Drugs Sales Value Share by Type (2021-2026) Table 22. Global Rheumatic Disease Drugs Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospital Table 24. Significant Companies of Clinic Table 25. Significant Companies of Others Table 26. Global Rheumatic Disease Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Rheumatic Disease Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Rheumatic Disease Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Rheumatic Disease Drugs Sales Value Share by Application (2021-2026) Table 30. Global Rheumatic Disease Drugs Sales Value Share by Application (2027-2032) Table 31. Global Rheumatic Disease Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Rheumatic Disease Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Rheumatic Disease Drugs Sales Value Share by Region (2021-2026) Table 34. Global Rheumatic Disease Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Rheumatic Disease Drugs Sales Value Share by Region (2027-2032) Table 36. Global Rheumatic Disease Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Rheumatic Disease Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Rheumatic Disease Drugs Sales Value Market Share by Country (2021-2026) Table 39. Global Rheumatic Disease Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Rheumatic Disease Drugs Sales Value Market Share by Country (2027-2032) Table 41. Simcere Company Information Table 42. Simcere Business Overview Table 43. Simcere Rheumatic Disease Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Simcere Rheumatic Disease Drugs Product Portfolio Table 45. Simcere Recent Development Table 46. WuXi AppTec Company Information Table 47. WuXi AppTec Business Overview Table 48. WuXi AppTec Rheumatic Disease Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. WuXi AppTec Rheumatic Disease Drugs Product Portfolio Table 50. WuXi AppTec Recent Development Table 51. Sanofi Company Information Table 52. Sanofi Business Overview Table 53. Sanofi Rheumatic Disease Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Sanofi Rheumatic Disease Drugs Product Portfolio Table 55. Sanofi Recent Development Table 56. Johnson & Johnson Company Information Table 57. Johnson & Johnson Business Overview Table 58. Johnson & Johnson Rheumatic Disease Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Johnson & Johnson Rheumatic Disease Drugs Product Portfolio Table 60. Johnson & Johnson Recent Development Table 61. Roche Company Information Table 62. Roche Business Overview Table 63. Roche Rheumatic Disease Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Roche Rheumatic Disease Drugs Product Portfolio Table 65. Roche Recent Development Table 66. Eli Lilly and Company Company Information Table 67. Eli Lilly and Company Business Overview Table 68. Eli Lilly and Company Rheumatic Disease Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Eli Lilly and Company Rheumatic Disease Drugs Product Portfolio Table 70. Eli Lilly and Company Recent Development Table 71. ALPHAMAB ONCOLOGY Company Information Table 72. ALPHAMAB ONCOLOGY Business Overview Table 73. ALPHAMAB ONCOLOGY Rheumatic Disease Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. ALPHAMAB ONCOLOGY Rheumatic Disease Drugs Product Portfolio Table 75. ALPHAMAB ONCOLOGY Recent Development Table 76. Hengrui Company Information Table 77. Hengrui Business Overview Table 78. Hengrui Rheumatic Disease Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Hengrui Rheumatic Disease Drugs Product Portfolio Table 80. Hengrui Recent Development Table 81. Pfizer Company Information Table 82. Pfizer Business Overview Table 83. Pfizer Rheumatic Disease Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Pfizer Rheumatic Disease Drugs Product Portfolio Table 85. Pfizer Recent Development Table 86. Henlius Company Information Table 87. Henlius Business Overview Table 88. Henlius Rheumatic Disease Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Henlius Rheumatic Disease Drugs Product Portfolio Table 90. Henlius Recent Development Table 91. Bristol-Myers Squibb Company Information Table 92. Bristol-Myers Squibb Business Overview Table 93. Bristol-Myers Squibb Rheumatic Disease Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Bristol-Myers Squibb Rheumatic Disease Drugs Product Portfolio Table 95. Bristol-Myers Squibb Recent Development Table 96. Amgen Company Information Table 97. Amgen Business Overview Table 98. Amgen Rheumatic Disease Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Amgen Rheumatic Disease Drugs Product Portfolio Table 100. Amgen Recent Development Table 101. AbbVie Company Information Table 102. AbbVie Business Overview Table 103. AbbVie Rheumatic Disease Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. AbbVie Rheumatic Disease Drugs Product Portfolio Table 105. AbbVie Recent Development Table 106. UCB Company Information Table 107. UCB Business Overview Table 108. UCB Rheumatic Disease Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. UCB Rheumatic Disease Drugs Product Portfolio Table 110. UCB Recent Development Table 111. Mitsubishi Tanabe Pharma Corporation Company Information Table 112. Mitsubishi Tanabe Pharma Corporation Business Overview Table 113. Mitsubishi Tanabe Pharma Corporation Rheumatic Disease Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Mitsubishi Tanabe Pharma Corporation Rheumatic Disease Drugs Product Portfolio Table 115. Mitsubishi Tanabe Pharma Corporation Recent Development Table 116. IQVIA Company Information Table 117. IQVIA Business Overview Table 118. IQVIA Rheumatic Disease Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. IQVIA Rheumatic Disease Drugs Product Portfolio Table 120. IQVIA Recent Development Table 121. Boehringer-Ingelheim Company Information Table 122. Boehringer-Ingelheim Business Overview Table 123. Boehringer-Ingelheim Rheumatic Disease Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Boehringer-Ingelheim Rheumatic Disease Drugs Product Portfolio Table 125. Boehringer-Ingelheim Recent Development Table 126. Aprazer Company Information Table 127. Aprazer Business Overview Table 128. Aprazer Rheumatic Disease Drugs Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. Aprazer Rheumatic Disease Drugs Product Portfolio Table 130. Aprazer Recent Development Table 131. Research Programs/Design for This Report Table 132. Authors List of This Report Table 133. Secondary Sources Table 134. Primary Sources List of Figures Figure 1. Rheumatic Disease Drugs Product Image Figure 2. Global Rheumatic Disease Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Rheumatic Disease Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Rheumatic Disease Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. DMARDs Image Figure 8. JAK Inhibitors Image Figure 9. Biologics Image Figure 10. Others Image Figure 11. Global Rheumatic Disease Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Rheumatic Disease Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Rheumatic Disease Drugs Sales Value Share by Type (2021-2032) Figure 14. Hospital Image Figure 15. Clinic Image Figure 16. Others Image Figure 17. Global Rheumatic Disease Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Rheumatic Disease Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Rheumatic Disease Drugs Sales Value Share by Application (2021-2032) Figure 20. Global Rheumatic Disease Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Rheumatic Disease Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Rheumatic Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 23. North America Rheumatic Disease Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Rheumatic Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Rheumatic Disease Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Rheumatic Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Rheumatic Disease Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Rheumatic Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. South America Rheumatic Disease Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Rheumatic Disease Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Rheumatic Disease Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • DMARDs
  • JAK Inhibitors
  • Biologics
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Simcere
  • WuXi AppTec
  • Sanofi
  • Johnson & Johnson
  • Roche
  • Eli Lilly and Company
  • ALPHAMAB ONCOLOGY
  • Hengrui
  • Pfizer
  • Henlius
  • Bristol-Myers Squibb
  • Amgen
  • AbbVie
  • UCB
  • Mitsubishi Tanabe Pharma Corporation
  • IQVIA
  • Boehringer-Ingelheim
  • Aprazer

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Rheumatic Disease Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Rheumatic Disease Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Rheumatic Disease Drugs Market Dynamics
  1. 2.1 Rheumatic Disease Drugs Industry Trends
  2. 2.2 Rheumatic Disease Drugs Industry Drivers
  3. 2.3 Rheumatic Disease Drugs Industry Opportunities and Challenges
  4. 2.4 Rheumatic Disease Drugs Industry Restraints
3 Rheumatic Disease Drugs Market by Company
  1. 3.1 Global Rheumatic Disease Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Rheumatic Disease Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Rheumatic Disease Drugs Company Ranking (2024-2026)
  4. 3.4 Global Rheumatic Disease Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Rheumatic Disease Drugs Company Product Type and Application
  6. 3.6 Global Rheumatic Disease Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Rheumatic Disease Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Rheumatic Disease Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Rheumatic Disease Drugs Market by Type
  1. 4.1 Rheumatic Disease Drugs Type Introduction
  2. 4.1.1 DMARDs
  3. 4.1.2 JAK Inhibitors
  4. 4.1.3 Biologics
  5. 4.1.4 Others
  6. 4.2 Global Rheumatic Disease Drugs Sales Value by Type
  7. 4.2.1 Global Rheumatic Disease Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Rheumatic Disease Drugs Sales Value by Type (2021-2032)
  9. 4.2.3 Global Rheumatic Disease Drugs Sales Value Share by Type (2021-2032)
5 Rheumatic Disease Drugs Market by Application
  1. 5.1 Rheumatic Disease Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Rheumatic Disease Drugs Sales Value by Application
  6. 5.2.1 Global Rheumatic Disease Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Rheumatic Disease Drugs Sales Value by Application (2021-2032)
  8. 5.2.3 Global Rheumatic Disease Drugs Sales Value Share by Application (2021-2032)
6 Rheumatic Disease Drugs Regional Value Analysis
  1. 6.1 Global Rheumatic Disease Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Rheumatic Disease Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Rheumatic Disease Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Rheumatic Disease Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Rheumatic Disease Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Rheumatic Disease Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Rheumatic Disease Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Rheumatic Disease Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Rheumatic Disease Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Rheumatic Disease Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Rheumatic Disease Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Rheumatic Disease Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Rheumatic Disease Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Rheumatic Disease Drugs Sales Value Share by Country, 2025 VS 2032
7 Rheumatic Disease Drugs Country-level Value Analysis
  1. 7.1 Global Rheumatic Disease Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Rheumatic Disease Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Rheumatic Disease Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Rheumatic Disease Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Rheumatic Disease Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Rheumatic Disease Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Rheumatic Disease Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Simcere
  2. 8.1.1 Simcere Company Information
  3. 8.1.2 Simcere Business Overview
  4. 8.1.3 Simcere Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Simcere Rheumatic Disease Drugs Product Portfolio
  6. 8.1.5 Simcere Recent Developments
  7. 8.2 WuXi AppTec
  8. 8.2.1 WuXi AppTec Company Information
  9. 8.2.2 WuXi AppTec Business Overview
  10. 8.2.3 WuXi AppTec Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 WuXi AppTec Rheumatic Disease Drugs Product Portfolio
  12. 8.2.5 WuXi AppTec Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Rheumatic Disease Drugs Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Johnson & Johnson
  20. 8.4.1 Johnson & Johnson Company Information
  21. 8.4.2 Johnson & Johnson Business Overview
  22. 8.4.3 Johnson & Johnson Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Johnson & Johnson Rheumatic Disease Drugs Product Portfolio
  24. 8.4.5 Johnson & Johnson Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Roche Rheumatic Disease Drugs Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Eli Lilly and Company
  32. 8.6.1 Eli Lilly and Company Company Information
  33. 8.6.2 Eli Lilly and Company Business Overview
  34. 8.6.3 Eli Lilly and Company Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Eli Lilly and Company Rheumatic Disease Drugs Product Portfolio
  36. 8.6.5 Eli Lilly and Company Recent Developments
  37. 8.7 ALPHAMAB ONCOLOGY
  38. 8.7.1 ALPHAMAB ONCOLOGY Company Information
  39. 8.7.2 ALPHAMAB ONCOLOGY Business Overview
  40. 8.7.3 ALPHAMAB ONCOLOGY Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 ALPHAMAB ONCOLOGY Rheumatic Disease Drugs Product Portfolio
  42. 8.7.5 ALPHAMAB ONCOLOGY Recent Developments
  43. 8.8 Hengrui
  44. 8.8.1 Hengrui Company Information
  45. 8.8.2 Hengrui Business Overview
  46. 8.8.3 Hengrui Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Hengrui Rheumatic Disease Drugs Product Portfolio
  48. 8.8.5 Hengrui Recent Developments
  49. 8.9 Pfizer
  50. 8.9.1 Pfizer Company Information
  51. 8.9.2 Pfizer Business Overview
  52. 8.9.3 Pfizer Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pfizer Rheumatic Disease Drugs Product Portfolio
  54. 8.9.5 Pfizer Recent Developments
  55. 8.10 Henlius
  56. 8.10.1 Henlius Company Information
  57. 8.10.2 Henlius Business Overview
  58. 8.10.3 Henlius Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Henlius Rheumatic Disease Drugs Product Portfolio
  60. 8.10.5 Henlius Recent Developments
  61. 8.11 Bristol-Myers Squibb
  62. 8.11.1 Bristol-Myers Squibb Company Information
  63. 8.11.2 Bristol-Myers Squibb Business Overview
  64. 8.11.3 Bristol-Myers Squibb Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bristol-Myers Squibb Rheumatic Disease Drugs Product Portfolio
  66. 8.11.5 Bristol-Myers Squibb Recent Developments
  67. 8.12 Amgen
  68. 8.12.1 Amgen Company Information
  69. 8.12.2 Amgen Business Overview
  70. 8.12.3 Amgen Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Amgen Rheumatic Disease Drugs Product Portfolio
  72. 8.12.5 Amgen Recent Developments
  73. 8.13 AbbVie
  74. 8.13.1 AbbVie Company Information
  75. 8.13.2 AbbVie Business Overview
  76. 8.13.3 AbbVie Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 AbbVie Rheumatic Disease Drugs Product Portfolio
  78. 8.13.5 AbbVie Recent Developments
  79. 8.14 UCB
  80. 8.14.1 UCB Company Information
  81. 8.14.2 UCB Business Overview
  82. 8.14.3 UCB Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  83. 8.14.4 UCB Rheumatic Disease Drugs Product Portfolio
  84. 8.14.5 UCB Recent Developments
  85. 8.15 Mitsubishi Tanabe Pharma Corporation
  86. 8.15.1 Mitsubishi Tanabe Pharma Corporation Company Information
  87. 8.15.2 Mitsubishi Tanabe Pharma Corporation Business Overview
  88. 8.15.3 Mitsubishi Tanabe Pharma Corporation Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Mitsubishi Tanabe Pharma Corporation Rheumatic Disease Drugs Product Portfolio
  90. 8.15.5 Mitsubishi Tanabe Pharma Corporation Recent Developments
  91. 8.16 IQVIA
  92. 8.16.1 IQVIA Company Information
  93. 8.16.2 IQVIA Business Overview
  94. 8.16.3 IQVIA Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  95. 8.16.4 IQVIA Rheumatic Disease Drugs Product Portfolio
  96. 8.16.5 IQVIA Recent Developments
  97. 8.17 Boehringer-Ingelheim
  98. 8.17.1 Boehringer-Ingelheim Company Information
  99. 8.17.2 Boehringer-Ingelheim Business Overview
  100. 8.17.3 Boehringer-Ingelheim Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Boehringer-Ingelheim Rheumatic Disease Drugs Product Portfolio
  102. 8.17.5 Boehringer-Ingelheim Recent Developments
  103. 8.18 Aprazer
  104. 8.18.1 Aprazer Company Information
  105. 8.18.2 Aprazer Business Overview
  106. 8.18.3 Aprazer Rheumatic Disease Drugs Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Aprazer Rheumatic Disease Drugs Product Portfolio
  108. 8.18.5 Aprazer Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst